TB Provider Toolkit

This page offers resources to assist health care professionals in providing tuberculosis (TB) care. Resources are listed in alphabetical order under each topic heading. TB topics include: Screening, Testing, Treatment and Consultation.

If you need assistance finding a resource or have resource suggestions, please email tbservices@doh.wa.gov

Screening

• Adult TB Risk Assessment (PDF)
  Use this tool to identify asymptomatic adults for latent TB infection (LTBI) testing.

• Pediatric TB Risk Assessment (PDF)
  Use this tool to identify asymptomatic children for LTBI testing.

• Tuberculosis Symptom Screening (PDF)
  Used when performing symptom screening for patients with prior TB infection or disease.

• USPSTF Final Recommendation Statement for Latent Tuberculosis Infection: Screening
  U.S. Preventive Services Task Force (USPSTF) recommends screening for TB infection in populations at increased risk.

Testing

• ATS/IDSA/CDC Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children
  Recommendations about the diagnosis of TB infection and TB disease in adults and children.

• The BCG World Atlas
  Provides information on BCG policies and practice for over 180 countries to assist clinicians with interpretation of TB diagnostics.

• TB Laboratory Diagnostics Summary (PDF)
  Provides an overview of the various laboratory tests used in the diagnosis and treatment of TB

• TST in 3D
  This online TST/IGRA interpreter estimates the risk of active tuberculosis for an adult based on his/her reaction to a tuberculin skin test (TST) or Interferon Gamma Release Assay (IGRA) and clinical profile.

• TST Ruler (PDF)
  Used to measure the raised skin reaction from a TST. Available to order from Centers for Disease Control and Prevention (CDC).

• Tuberculin Skin Test Record (PDF)
  This publication records skin testing information.​

Treatment

• LTBI Treatment Guidance in Washington State, updated 5/2022 (PDF) and LTBI Treatment Quick Reference Sheet (PDF). Provides guidance on using rifamycin-based, shorter course regimens for treating LTBI.

• Rifampin and Rifapentine Supply Issues: On September 14, 2020 the CDC posted a Dear Colleague Letter about some current rifamycin issues. The letter includes FDA's work to mitigate shortages as well as its interim guidance regarding the continued use of rifampin and rifapentine. The Washington State TB Program recommends that providers treating TB patients review this letter. The CDC's letter can be found on the CDC website here: https://www.cdc.gov/tb/publications/letters/Rifamycin_Update.html

  The FDA has more information about nitrosamines posted on this page: https://www.fda.gov/drugs/drug-safety-and-availability/information-about-nitrosamine-impurities-medications

  If you have questions or if you have difficulty accessing these medications please reach out to us at TBServices@doh.wa.gov

• ATS/IDSA/CDC Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
  Recommendations on the clinical and public health management of TB in children and adults.

• Latent TB Infection Resources - CDC
  CDC's one-stop-shop for LTBI information, guidance, and educational materials.

• Managing Drug Interactions in the Treatment of HIV-Related TB
  Provides guidelines for treating HIV and TB together.

• TB Free California Resources for Providers
  Includes scripts of how to talk to patients about LTBI, a 3HP drug interactions guide, LTBI treatment cards, etc.

• TB Patient Resources
  Includes patient education materials in multiple languages and resources on providing culturally appropriate TB care.

Consultation

TB Project ECHO
A videoconference meeting tor clinicians to get consultation on TB infection or TB disease cases and participate in case-based learning and TB-related didactics.